ରିପ୍ରେଟିନିବ

ରିପ୍ରେଟିନିବ
Clinical data
Pronunciation	rip re' ti nib
Trade names	Qinlock
Synonyms	DCC-2618
AHFS/Drugs.com	monograph
MedlinePlus	a620035
data	US DailyMed: Ripretinib;
Pregnancy; category	AU: D ; Use should be avoided;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ;
Identifiers
	IUPAC name 3-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl}-1-phenylurea;
Chemical and physical data
Formula	C24H21BrFN5O2
Molar mass	୫୧୦.୩୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1;
	InChI InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33); Key:CEFJVGZHQAGLHS-UHFFFAOYSA-N;

ରିପ୍ରେଟିନିବ (ଇଂରାଜୀ ଭାଷାରେ Ripretinib), କିନଲକ ଏହାର ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ପାକଅନ୍ତନଳୀ ଷ୍ଟ୍ରୋମାଲ୍ ଟ୍ୟୁମର (ଜିଏସ୍ଟି) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ଅତି କମରେ ୩ ପ୍ରକାର ଚିକିତ୍ସାରେ ବିଫଳ ହୋଇଥିବା କ୍ଷେତ୍ରରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କେଶହାନୀ, ଥକାପଣ, ଅଇ, ପେଟ ଯନ୍ତ୍ରଣା, କୋଷ୍ଠକାଠିନ୍ୟ, ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା, ତରଳ ଝାଡ଼ା, ଏବଂ ପାପୁଲି-ପ୍ଲାଦର ରାସ ଯାହା ଏରିଥ୍ରୋଡାଇସେସ୍ଥେସିଆ ସିଣ୍ଡ୍ରୋମ ନାମରେ ମଧ୍ୟ ଜଣାଶୁଣା ।^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଚର୍ମ କର୍କଟ ଏବଂ କ୍ଷତ ଭଲ ଭାବରେ ଶୁଖେନି । ^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି କରିପାରେ । ^[୪] ଏହା ଏକ କାଇନେଜ ଇନହିବିଟର ।^[୪]

୨୦୨୦ ମସିହାରେ ଅଷ୍ଟ୍ରେଲିଆ ଏବଂ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ରିପ୍ରେଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ଏହା ବାବଦ ମାସକୁ ପ୍ରାୟ ୩୫,୦୦୦ ଖର୍ଚ୍ଚ ହୁଏ ।^[୫] ୨୦୨୧ ସୁଦ୍ଧା ୟୁରୋପରେ ଅନୁମୋଦନ ବିଚାରାଧୀନ ଥିଲା ।^[୬]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Qinlock Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 21 July 2020. Archived from the original on 13 August 2020. Retrieved 17 August 2020.
↑ "FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors". U.S. Food and Drug Administration (FDA) (Press release). 15 May 2020. Archived from the original on 15 May 2020. Retrieved 15 May 2020. This article incorporates text from this source, which is in the public domain.
↑ ^୩.୦ ^୩.୧ ^୩.୨ "Ripretinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 November 2020. Retrieved 18 October 2021.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "DailyMed - QINLOCK- ripretinib tablet". dailymed.nlm.nih.gov. Archived from the original on 28 February 2021. Retrieved 18 October 2021.
↑ "Qinlock Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 17 November 2021. Retrieved 18 October 2021.
↑ "Ripretinib". SPS - Specialist Pharmacy Service. 26 February 2019. Archived from the original on 18 October 2021. Retrieved 18 October 2021.

[Au2021-1] ୧.୦ ^୧.୧ ^୧.୨ "Qinlock Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 21 July 2020. Archived from the original on 13 August 2020. Retrieved 17 August 2020.

[FDA_PR-2] "FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors". U.S. Food and Drug Administration (FDA) (Press release). 15 May 2020. Archived from the original on 15 May 2020. Retrieved 15 May 2020. This article incorporates text from this source, which is in the public domain.

[AHFS2021-3] ୩.୦ ^୩.୧ ^୩.୨ "Ripretinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 November 2020. Retrieved 18 October 2021.

[PI2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "DailyMed - QINLOCK- ripretinib tablet". dailymed.nlm.nih.gov. Archived from the original on 28 February 2021. Retrieved 18 October 2021.

[5] "Qinlock Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 17 November 2021. Retrieved 18 October 2021.

[6] "Ripretinib". SPS - Specialist Pharmacy Service. 26 February 2019. Archived from the original on 18 October 2021. Retrieved 18 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]